Heat shock protein 90 (Hsp90) is a highly conserved molecular chaperone that regulates the maturation of various client proteins. Most therapeutic studies have focused on N-terminal Hsp90 inhibitors, but these are limited by dose-escalating toxicities that are caused by induction of the heat shock response. Leonard Neckers’ discovery of novobiocin as a Hsp90 C-terminal inhibitor revealed an alternative mode to Hsp90 inhibition and established the C-terminal domain (CTD) as a therapeutic target. This review highlights recent advances in Hsp90 CTD inhibition and summarizes the evolution of novobiocin-based C-terminal inhibitors. Structure-activity relationship studies are discussed, demonstrating how medicinal chemistry optimization has produced CTD modulators with selective anti-proliferative or neuroprotective activities.
Jiang et al. (Sun,) studied this question.